Comparative Pharmacology
Head-to-head clinical analysis: APTENSIO XR versus DESOXYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APTENSIO XR versus DESOXYN.
APTENSIO XR vs DESOXYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Central alpha-2 adrenergic agonist that selectively stimulates alpha-2 adrenergic receptors in the brain stem, reducing sympathetic outflow and decreasing peripheral vascular resistance, heart rate, and blood pressure.
Desoxyn (methamphetamine) is a sympathomimetic amine that promotes release of catecholamines (primarily dopamine and norepinephrine) from presynaptic nerve terminals, blocks their reuptake, and inhibits monoamine oxidase (MAO) activity. It produces CNS stimulation and peripheral alpha- and beta-adrenergic effects.
Oral, 20 mg once daily in the morning; may increase by 10–20 mg/day at 3-day intervals up to a maximum of 60 mg/day.
Adults: 5-60 mg/day orally in divided doses, typically starting at 5 mg twice daily; maximum 60 mg/day.
None Documented
None Documented
The terminal elimination half-life of methylphenidate (IR and extended-release) is approximately 3-4 hours in children and 3.5-5 hours in adults. For Aptensio XR, the half-life is about 4-5 hours, supporting twice-daily dosing.
Terminal elimination half-life: 9–14 hours (mean 12 hours) in adults; prolonged in alkaline urine (up to 25–30 hours). Clinically, twice-daily dosing maintains steady state after 2–3 days.
Methylphenidate is primarily excreted renally as metabolites (80-90%), with 1-3% excreted unchanged. Biliary/fecal elimination accounts for <5%.
Renal: ~90% as unchanged drug and metabolites (primarily 4-hydroxyephedrine and 4-hydroxynorephedrine) within 48 hours; urinary pH-dependent: acidic urine increases elimination. Biliary/fecal: minor.
Category C
Category C
CNS Stimulant
CNS Stimulant